Abstract
Background The continuing increase in syphilis rates worldwide necessitates development of a vaccine with global efficacy. We conducted a multi-center, observational study to explore Treponema pallidum subsp. pallidum (TPA) molecular epidemiology essential for vaccine research by analyzing clinical data and specimens from early syphilis patients using whole-genome sequencing (WGS) and publicly available WGS data.
Methods We enrolled patients with primary (PS), secondary (SS) or early latent (ELS) syphilis from clinics in China, Colombia, Malawi and the United States between November 2019 - May 2022. Inclusion criteria included age ≥18 years, and syphilis confirmation by direct detection methods and/or serological testing. TPA detection and WGS were conducted on lesion swabs, skin biopsies/scrapings, whole blood, and/or rabbit-passaged isolates. We compared our WGS data to publicly available genomes, and analysed TPA populations to identify mutations associated with lineage and geography.
Findings We screened 2,820 patients and enrolled 233 participants - 77 (33%) with PS, 154 (66%) with SS, and two (1%) with ELS. Median age of participants was 28; 66% were cis-gender male, of which 43% reported identifying as “gay”, “bisexual”, or “other sexuality”. Among all participants, 56 (24%) had HIV co-infection. WGS data from 113 participants demonstrated a predominance of SS14-lineage strains with geographic clustering. Phylogenomic analysis confirmed that Nichols-lineage strains are more genetically diverse than SS14-lineage strains and cluster into more distinct subclades. Differences in single nucleotide variants (SNVs) were evident by TPA lineage and geography. Mapping of highly differentiated SNVs to three-dimensional protein models demonstrated population-specific substitutions, some in outer membrane proteins (OMPs) of interest.
Interpretation Our study involving participants from four countries substantiates the global diversity of TPA strains. Additional analyses to explore TPA OMP variability within strains will be vital for vaccine development and improved understanding of syphilis pathogenesis on a population level.
Funding National Institutes of Health, Bill and Melinda Gates Foundation
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; ACS reports royalties from UptoDate Inc, ELM reports research grants from Sanofi Pasteur, Janssen, Moderna and GSK, grants and consulting fees from Takeda and MSD, and honoraria from Pfizer, JAG reports support for attending meetings/travel from Janssen, MAM reports membership in an advisory board for GSK, JDR receives royalties from Biokit SA, Chembio, and Span Diagnostics for syphilis serodiagnostic reagents outside the scope of the current work, JBP reports research support from Gilead Sciences, non-financial support from Abbott Diagnostics, and consulting for Zymeron Corporation; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This project was funded by the US National Institutes of Health National Institute for Allergy and Infectious Disease (U19AI144177 to JDR and MAM). This work also was supported, in part, by the Bill & Melinda Gates Foundation (INV-036560 to ACS), strategic research dollars from Connecticut Childrens, the National Institute of Virology and Bacteriology (Programme EXCELES, ID Project No. LX22NPO5103, Funded by the European Union - Next Generation EU) to DS. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. JAGL was supported by an International Masters Fellowship of the Wellcome Trust (reference number: 214641/Z/18/Z) and a Global Infectious Diseases Research Training grant of the Fogarty International Center (award number D43TW006589). Finally, the collection of samples of the other longitudinal study in Colombia that were included in the genomic analysis of TPA was supported by funds provided by Connecticut Childrens.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board (IRB) at the University of North Carolina at Chapel Hill (UNC) gave ethical approval for this work (UNC IRB protocol number 19-0311). In addition, the ethics committees/IRBs at Southern Medical University (SMU) in Guangzhou, China (Medical Ethics Committee IRB protocol number GDDHLS-20181202 [R3]; at the Centro Internacional de Entrenamiento e Investigaciones Medicas (CIDEIM) in Cali, Colombia (CIDEIM Institutional Human Research Ethics Committee IRB 163, protocol number 1289), and at UNC Project Malawi in Lilongwe, Malawi (IRB Approval Number 2252) Number 19-0311) gave ethical approval for this work. At the SMU site in China, rabbit experimentation was approved by the Ethics Committee of SMU Experimental Animal Ethics Committee (L2018277) and South China Agricultural University Experimental Animal Ethics Committee (2020C004).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The study protocol and English case report forms are included in the Supplementary Methods. The deidentified participant REDCap database will be made publicly available at the time of publication. Requests to share the informed consent forms and database can be made by emailing the corresponding author at idrod{at}med.unc.edu. Raw sequencing data from this study with residual human reads removed are available through the Sequence Read Archive (SRA, BioProject PRJNA815321). Data supporting the findings of this study are available within the manuscript and Supplementary material.
